CRDL.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:48):

Stats
Today's Volume	24 443.00
Average Volume	153 985
Market Cap	166.58M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $-0.130 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.55
ATR14	$0.0110 (0.45%)

Volume Correlation

Long: -0.24 (neutral)

Short: -0.74 (moderate negative)

Signal:(47.663) Neutral

CARDIOL THERAPEUTICS INC Correlation

10 Most Positive Correlations
AAX.V	0.802
ORL.TO	0.802

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CARDIOL THERAPEUTICS INC Correlation - Currency/Commodity

-0.10
( neutral )

-0.11
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.05
( neutral )

-0.37
( neutral )

CARDIOL THERAPEUTICS INC Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2023
Revenue:	$0
Gross Profit:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2022
Revenue:	$0
Gross Profit:	$-219 908 (0.00 %)
EPS:	$-0.180

FY	2021
Revenue:	$78 760.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

CARDIOL THERAPEUTICS INC

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.